Forte Biosciences, Inc. Stock price

Equities

FBRX

US34962G1094

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-29 pm EST 5-day change 1st Jan Change
0.6828 USD -5.17% Intraday chart for Forte Biosciences, Inc. -0.52% -16.90%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Enjoy this offer
* See conditions on site
Sales 2023 * - Sales 2024 * - Capitalization 26.16M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 9
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.17%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.17%
1 week-0.52%
Current month+11.92%
1 month-8.63%
3 months+47.60%
6 months-17.64%
Current year-16.90%
More quotes
1 week
0.65
Extreme 0.65
0.73
1 month
0.44
Extreme 0.44
0.73
Current year
0.44
Extreme 0.44
0.85
1 year
0.38
Extreme 0.38
1.29
3 years
0.38
Extreme 0.38
43.57
5 years
0.38
Extreme 0.38
53.99
10 years
0.38
Extreme 0.38
53.99
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 16-12-31
President 55 22-06-06
Director of Finance/CFO 57 20-02-29
Members of the board TitleAgeSince
Director/Board Member 68 23-01-09
Director/Board Member 56 20-05-31
Director/Board Member 65 22-05-11
More insiders
Date Price Change Volume
24-02-29 0.6828 -5.17% 25,046
24-02-28 0.72 +5.08% 123,167
24-02-27 0.6852 -0.84% 56,340
24-02-26 0.691 +0.14% 17,649
24-02-23 0.69 +4.39% 16,301

Delayed Quote Nasdaq, February 29, 2024 at 04:00 pm EST

More quotes
Forte Biosciences, Inc. is a biopharmaceutical company. The Company is advancing through preclinical trials its product candidate, FB-102, which is a therapeutic molecule with potentially autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo and alopecia areata (AA). FB-102 is an antagonist of autoimmune disease pathways with the potential for a durable response. The Company's subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Emerald Limited.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6828 USD
Average target price
3 USD
Spread / Average Target
+339.37%
Consensus
  1. Stock
  2. Equities
  3. Stock Forte Biosciences, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW